Selegiline is a monoamine oxidase inhibitor used to treat major depressive disorder and Parkinson's. Identification · Pharmacology · Interactions · Products

It is used in newly diagnosed patients with Parkinson's disease. It may slow progression of the clinical disease and delay the requirement for levodopa therapy.

Selegiline (deprenyl) is a selective inhibitor of cerebral monoamine oxidase type B at the dosage (10 mg/day) used in patients with Parkinson's disease. Through ...

Abstract. Although being a drug therapeutically used for a long time, the enzymatic metabolism of selegiline has not been adequately studied.

Deprenyl (selegiline), a selective MAO-B inhibitor with active metabolites; effects on locomotor activity, dopaminergic neurotransmission and firing rate of ...

Abstract. Selegiline (deprenyl), a selective, irreversible inhibitor of monoamine oxidase type B (MAO-B) is widely used in the treatment of Parkinson's ...

Selegiline (l-deprenyl) is in clinical treatment trials as a potential smoking cessation drug. We investigated the affect of selegiline and its metabolites on ...

Major circulating metabolite? No; Spontaneous? No; Activity: unknown; References. Brown CM, Reisfeld B, Mayeno AN: Cytochromes P450: a structure-based ...

Selegiline, a selective monoamine oxidase B inhibitor, has been approved for the adjunctive treatment of Parkinson's disease at low doses. At higher doses, oral ...

The selegiline pharmacokinetics differed greatly between the 2 routes of administration. Transdermal selegiline administration reduced metabolism and produced a ...